Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
OTHER OTC:SPRB
Total Valuation
Spruce Biosciences has a market cap or net worth of $2.66M. The enterprise value is ―.
Market Cap$2.66M
Enterprise Value―
Share Statistics
Spruce Biosciences has 42,231,285 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,231,285
Owned by Insiders13.46%
Owned by Institutions17.56%
Financial Efficiency
Spruce Biosciences’s return on equity (ROE) is -1.84 and return on invested capital (ROIC) is -177.78%.
Return on Equity (ROE)-1.84
Return on Assets (ROA)-1.17
Return on Invested Capital (ROIC)-177.78%
Return on Capital Employed (ROCE)-1.87
Revenue Per Employee245.55K
Profits Per Employee-2.65M
Employee Count20
Asset Turnover0.11
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spruce Biosciences is -0.33. Spruce Biosciences’s PEG ratio is -0.02.
PE Ratio-0.33
PS Ratio0.00
PB Ratio0.11
Price to Fair Value0.60
Price to FCF-0.12
Price to Operating Cash Flow-0.12
PEG Ratio-0.02
Income Statement
In the last 12 months, Spruce Biosciences had revenue of 4.91M and earned -53.04M in profits. Earnings per share was -1.29.
Revenue4.91M
Gross Profit4.91M
Operating Income-56.15M
Pretax Income-53.04M
Net Income-53.04M
EBITDA-56.15M
Earnings Per Share (EPS)-1.29
Cash Flow
In the last 12 months, operating cash flow was -46.50M and capital expenditures 0.00, giving a free cash flow of -46.50M billion.
Operating Cash Flow-46.50M
Free Cash Flow-46.50M
Free Cash Flow per Share-1.10
Dividends & Yields
Spruce Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.15
52-Week Price Change-91.18%
50-Day Moving Average0.18
200-Day Moving Average0.38
Relative Strength Index (RSI)17.54
Average Volume (3m)2.65M
Important Dates
Spruce Biosciences upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Spruce Biosciences as a current ratio of 2.90, with Debt / Equity ratio of 6.26%
Current Ratio2.90
Quick Ratio2.90
Debt to Market Cap0.14
Net Debt to EBITDA0.65
Interest Coverage Ratio182.90
Taxes
In the past 12 months, Spruce Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Spruce Biosciences EV to EBITDA ratio is 0.34, with an EV/FCF ratio of 0.34.
EV to Sales-3.88
EV to EBITDA0.34
EV to Free Cash Flow0.34
EV to Operating Cash Flow0.34
Balance Sheet
Spruce Biosciences has $60.05M in cash and marketable securities with $3.23M in debt, giving a net cash position of -$56.83M billion.
Cash & Marketable Securities$60.05M
Total Debt$3.23M
Net Cash-$56.83M
Net Cash Per Share-$1.35
Tangible Book Value Per Share$0.70
Margins
Gross margin is -14.36%, with operating margin of -1143.37%, and net profit margin of -1079.94%.
Gross Margin-14.36%
Operating Margin-1143.37%
Pretax Margin-1079.94%
Net Profit Margin-1079.94%
EBITDA Margin-1143.37%
EBIT Margin-1086.19%
Analyst Forecast
The average price target for Spruce Biosciences is $0.75, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$0.75
Price Target Upside1150.00% Upside
Analyst ConsensusHold
Analyst Count4
Revenue Growth Forecast-51.32%
EPS Growth Forecast-1.76%